Results 71 to 80 of about 46,834 (302)

Cost-benefit analysis of haemodialysis in patients with end-stage kidney disease in Abuja, Nigeria

Health Economics Review
Background Significant gaps in scholarship on the cost-benefit analysis of haemodialysis exist in low-middle-income countries, including Nigeria. The study, therefore, assessed the cost-benefit of haemodialysis compared with comprehensive conservative ...
Yakubu Adole Agada-Amade, Daniel Chukwuemeka Ogbuabor, Eric Obikeze, Ejemai Eboreime, Obinna Emmanuel Onwujekwe   +4 more
doaj   +1 more source

Explaining Indonesian Patients’ Experiences About Changes in the Hemodialysis Cost System

Enfermería Global
Aim: To explore the experience of haemodialysis patients in Indonesia over a decade, amidst changes in the cost system in hospitals. Since its implementation, the Universal Health Coverage (UHC) policy has significantly influenced haemodialysis services
Lailatun Nimah, Nursalam Nursalam, Andri Setiya Wahyudi, Herdina Mariyanti, Duangporn Piyakong   +4 more
doaj   +1 more source

Current practice and guideline adherence in renal dose adjustment for patients with chronic kidney disease: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims To quantify prescribing adherence to renal dosing recommendations in adults with chronic kidney disease (CKD; Stage 3 and above) and to evaluate the clinical consequences of non‐adherence. Methods This systematic review and meta‐analysis was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD42025620883).
Hager ElGeed, Ahmed Tehemar, Mohamed Gasimelseed, Ahmed Gharaibeh, Muhammad Abdul Hadi, Kazeem Yusuff, Amani Zidan, Ahmed Awaisu   +7 more
wiley   +1 more source

Willingness to pay for haemodialysis among patients with chronic kidney disease in Abuja, Nigeria

BMC Nephrology
Background Evidence of willingness to pay for kidney replacement therapy is scarce in low-middle-income countries, including Nigeria’s Formal Sector Social Health Insurance Programme.
Yakubu Adole Agada-Amade, Daniel Chukwuemeka Ogbuabor, Eric Obikeze, Ejemai Eborieme, Obinna Emmanuel Onwujekwe   +4 more
doaj   +1 more source

Risk factors for hepatitis C virus sero-positivity among haemodialysis patients receiving care at Kidney Centre in a tertiary health facility in Maiduguri, Nigeria

The Pan African Medical Journal, 2014
Hepatitis C virus (HCV) is an important health care problem in haemodialysis. Hepatitis C virus is both a cause and complication of kidney diseases. Yet there are limited information on antibody against HCV in patients on haemodialysis.
Ibrahim Ummate, Ballah Akawu Denue, Ibrahim Musa Kida, Onah Joseph Ohioma, David Nadeba Bukbuk, Baba Waru Goni   +5 more
doaj   +1 more source

Mechanistic models for intermittent haemodialysis and haemodiafiltration clearance

British Journal of Clinical Pharmacology, EarlyView.
Haemodialysis has been used clinically for more than 70 years, but data regarding the clearance of medicines during dialysis are often based on studies with outdated, less efficient dialysers. Moreover, dialysis clearance is still frequently estimated using empirical approaches which lack mechanistic interpretability, are not readily generalizable ...
Laila Nassar, Nick Holford, Daniel Kurnik   +2 more
wiley   +1 more source

Nursing a patient on haemodialysis

, 2009
This chapter explores nursing a patient on haemodialysis, including nursing care of vascular access, pre- and post-operative care of access, cannulation of fistulae, complications of fistulae and their management, grafts, percutaneous tunnelled and ...
Edwina Brown, Anastasia Lawrence, Christine Daley, Jeremy Levy   +3 more
core   +1 more source

Comparing outcomes using low‐dose apixaban and anti‐Xa monitoring and vitamin K antagonists in patients with renal replacement therapy

British Journal of Clinical Pharmacology, EarlyView.
Background Guidelines recommend oral anticoagulation for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism. Outside the United States, apixaban is unlicensed for use in patients with end‐stage renal disease (ESRD) receiving renal replacement therapy (RRT).
John K. Bartoli‐Abdou, Alexander T. Cohen, Lucy Vernon, Victoria Collings, Ubonphan Chaichana, Natasha Moore, Hamda Jibril, Li Wei, Nicola Kumar, Karen A. Breen, Andrew J. Doyle   +10 more
wiley   +1 more source

Prevalence and risk factors associated with the severity of depression in patients with end-stage renal disease undergoing haemodialysis in southern Algeria.

Avicenna Medical Research
SUMMARY Introduction:  The management of patients suffering from end-stage chronic renal failure on haemodialysis is a major public health issue.
I BARKATI, A MESSAOUDI, T RAYANE, S AMERIT, R TALHI, A NEBAB   +5 more
doaj   +1 more source

Assessing kidney function for drug dosing in critical illness

British Journal of Clinical Pharmacology, EarlyView.
Kidney‐function assessment supports drug dosing in critical illness but does not directly measure drug clearance. Reduced creatinine generation, fluid shifts and rapidly changing filtration can make creatinine‐based estimates misleading, whereas genuinely augmented renal clearance can cause insufficient drug exposure. These processes can coexist.
Ming‐Shen Lin, Kuo‐Fan Liao
wiley   +1 more source